0A8I Stock Overview
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Genprex, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.28 |
| 52 Week High | US$42.37 |
| 52 Week Low | US$2.15 |
| Beta | -0.63 |
| 1 Month Change | -19.75% |
| 3 Month Change | -62.16% |
| 1 Year Change | -93.02% |
| 3 Year Change | -98.18% |
| 5 Year Change | n/a |
| Change since IPO | -98.56% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0A8I | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | 4.0% | 2.7% |
| 1Y | -93.0% | -23.5% | 5.2% |
Return vs Industry: 0A8I underperformed the UK Biotechs industry which returned -23.5% over the past year.
Return vs Market: 0A8I underperformed the UK Market which returned 5.2% over the past year.
Price Volatility
| 0A8I volatility | |
|---|---|
| 0A8I Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 8.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0A8I's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 0A8I's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 26 | John Varner | www.genprex.com |
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company’s lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes. Its product pipeline comprises Acclaim-1, which is in phase 2a clinical trial for the treatment of non-small cell lung cancer; Acclaim-2, which is in phase phase 1/2 clinical trial for the treatment of non-small cell lung cancer; and Acclaim-3, which is in phase 1/2 clinical trial for the treatment of small cell lung cancer.
Genprex, Inc. Fundamentals Summary
| 0A8I fundamental statistics | |
|---|---|
| Market cap | US$4.89m |
| Earnings (TTM) | -US$30.86m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.2x
P/E RatioIs 0A8I overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0A8I income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$30.86m |
| Earnings | -US$30.86m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -14.70 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 0A8I perform over the long term?
See historical performance and comparison